NCT00565318View on ClinicalTrials.gov

Benfotiamine in Diabetic Nephropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Diabetic Nephropathy
Interventions
DRUG

Benfotiamine

3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.

DRUG

Placebo

3x 1 film coated tablet daily. Duration: 12 weeks.

Trial Locations (1)

8000 GK

Isala Klinieken Hospital, Zwolle

Sponsors

Collaborators (1)

Predictions Network
All Listed Sponsors
collaborator

Isala

OTHER

collaborator

Wörwag Pharma GmbH & Co. KG

UNKNOWN

collaborator

Predictions Network

UNKNOWN

lead

University Medical Center Groningen

OTHER

NCT00565318 - Benfotiamine in Diabetic Nephropathy | Biotech Hunter | Biotech Hunter